Background: Prostate-specific membrane antigen (PSMA)-targeted radioguided surgery (PSMA-RGS) is a promising intraoperative technique for improving lesion localization and surgical accuracy in prostate cancer (PCa), particularly in high-risk or recurrent cases. Objective: To systematically evaluate the diagnostic performance of PSMA-RGS in PCa using multilevel meta-analysis. Methods: Following PRISMA 2020 guidelines, we searched PubMed, Embase, and Web of Science for clinical studies published between January 2016 and May 2025, with the final search performed on May 1, 2025, and identified 28 eligible studies. Diagnostic accuracy was assessed at the patient,...

BACKGROUND: Intra-abdominal desmoid tumours (IADT) can closely mimic gastrointestinal stromal tumours (GISTs), particularly in recurrence and metastases. However, differentiating these two diseases using radiological methods remains challenging. This study aimed to investigate the value of [ 18F]FAPI-42 PET/CT in differentiating IADT and GISTs compared to [ 18F]FDG PET/CT. METHODS: This study retrospectively included a total of 24 patients (12 patients with IADT and 12 patients with recurrent/metastatic GISTs) who underwent two separate PET/CT scans using [ 18F]FAPI-42 and [ 18F]FDG, respectively. The differences in tumour SUV max on...

Fibroblast activation protein-targeted radionuclide therapy (FAP-TRT) has emerged as a novel strategy for modulating the tumour microenvironment (TME) by selectively eradicating FAP-expressing cancer-associated fibroblasts (CAFs). Although preclinical studies have demonstrated promising results across various tumour models using diverse radiolabelled FAP inhibitors, clinical translation remains limited by modest efficacy, short tumour retention, and highly heterogeneousresponses. This review aims to provide an overview of recent advances in radiopharmaceutical design to enhance tumour targeting and prolong retention. Furthermore, we summarise early clinical findings and ongoing trials, while emphasising the potential translational...

BACKGROUND: Brentuximab vedotin combined with doxorubicin, vinblastine, and dacarbazine (A-AVD) improves outcomes in advanced-stage classic Hodgkin lymphoma, but patients with a positive early interim PET have inferior prognosis. We evaluated whether very early [ 18F]fluorodeoxyglucose ([ 18F]FDG)-PET-guided treatment adaptation after one cycle of A-AVD improves activity while limiting exposure to intensive chemotherapy. METHODS: This single-arm, multicentre, phase 2 trial was conducted at 16 centres in seven countries (the Netherlands, Spain, Denmark, Belgium, Portugal, Slovakia, and Poland). Adults aged 18-60 years with previously untreated advanced-stage classic Hodgkin lymphoma, WHO...